Expert Opinion on Investigational Drugs
Q1 Journal
Journal
Country
United Kingdom
Western Europe
Subject Area and Category
Medicine
└
Medicine (miscellaneous)
Q1
└
Pharmacology
Q1
└
Pharmacology (medical)
Q1
Publisher
SJR 2025
1.199
Q1
SJR Score
H-Index
126
Citations / Doc (2yr)
4.22
Total Docs. (latest)
86
Total Citations (3yr)
1,355
Publication type
Journals
ISSN
13543784, 17447658
Coverage
1994-2026
Journal Rank
#3,637
Subject Categories
Medicine (miscellaneous)
Q1
Pharmacology
Q1
Pharmacology (medical)
Q1
Subject Areas
Aims & Scope
Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development.
The Editors welcome:
Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies
Drug Evaluations reviewing the clinical and pharmacological data on a particular drug
Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials
The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.
Abstracting & Indexing
Scopus
Google Scholar
Web of Science
Medline
Embase
Detailed Metrics
| Total Docs. (latest) | 86 |
| Total Docs. (3 years) | 323 |
| Total Refs. | 6,602 |
| Total Citations (3 years) | 1,355 |
| Citable Docs. (3 years) | 296 |
| Citations / Doc. (2 years) | 4.22 |
| Ref. / Doc. | 76.77 |
| % Female | 43.6% |
Metrics Visualization
Latest year data vs 3-year cumulative figures
Publication & Citation Trend
Loading trend data from Crossref...
Top 10 Most Cited Articles
Loading articles...
Researcher Reviews
Write a ReviewNo reviews yet for this journal.
Be the first to share your experience!
Share Your Experience
Your review will be published after moderation. Email will not be displayed publicly.